RESUMO
La mesalazina (ácido 5-aminosalicilico,5-ASA) es un fármaco antiinflamatorio utilizado en primera línea del tratamiento de la enfermedad inflamatoria intestinal. Aunque se ha descrito la presentación de cólicos nefríticos como efecto adverso con su uso, apenas se encuentran publicados casos de nefrolitiasis medicamentosa por mesalazina, probablemente infradiagnósticado por no utilizar la metodología adecuada para el análisis de los cálculos. Presentamos dos casos de litiasis en dos pacientes tratados a altas dosis de mesalazina, efecto adverso a tener en cuenta y que ni siquiera es citado en la ficha técnica del medicamento
Mesalazine (5-aminosalicylic acid, 5-ASA), is an anti-inflammatory drug well-established as first-line treatment in the management of inflammatory bowel disease. Nephritic colic has been described as an uncommon side effect, but very few mesalazine nephrolithiasis have been published in the literature, probably due to its underdiagnosis for not using appropriate methodology for calculi analysis. We present two cases of lithiasis in patients treated with mesalazine at high dosage, an adverse effect to be taken into account as a drug lithiasis and which is not even mentioned in the patient information leaflet
